CD8A and neoplasm: Since the simultaneous depletion of CD4+ and CD8+ effector T cells after vaccination did not completely abrogate tumor protection (Figure 4A), we hypothesized that CD4+ T cells may contribute to the antitumor effect of VRP-TRP2 through the activation of B cell responses and therefore investigated a role for humoral immunity.